Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14391447 | 1.00 | USP2 (0.34) | USP2HSD17B10TDP1LMNATHRB | |
| SCHEMBL14628004 | 0.91 | ALDH1A1 (0.37) | LMNATHRBL3MBTL1 | |
| SCHEMBL13573098 | 0.89 | LMNA (0.38) | TDP1LMNATHRBL3MBTL1 | |
| SCHEMBL9443589 | 0.89 | LMNA (0.38) | TDP1LMNATHRBL3MBTL1 | |
| SCHEMBL1362342 | 0.84 | USP2 (0.35) | USP2HSD17B10TDP1LMNAL3MBTL1 | |
| SCHEMBL5023256 | 0.84 | USP2 (0.46) | USP2LMNATHRB | |
| SCHEMBL1362287 | 0.79 | LMNA (0.35) | TDP1LMNATHRBL3MBTL1 | |
| SCHEMBL12846443 | 0.79 | TSHR (0.45) | USP2LMNATHRB | |
| SCHEMBL26641882 | 0.77 | HSD17B10 (0.39) | HSD17B10TDP1LMNATHRB | |
| SCHEMBL3229121 | 0.75 | USP2 (0.38) | USP2HSD17B10TDP1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219161-A1 | Preparation Process Of Oligoglycosaminoglycan, And Reducing End Glucuronic Acid Type Oligochondroitin Sulfate And Pharmaceutical Composition Comprising The Same | OSTC, B3GAT3, CSGALNACT1 | USP2 1408/4885HSD17B10 698/4885TDP1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.